Analysis of veno-venous extracorporeal membrane oxygenation treatment strategies and literature review for the first case of human infection with H10N3 avian influenza complicated by severe acute respiratory distress syndrome in Guangxi

doi:10.19871/j.cnki.xfcrbzz.2025.02.001

Abstract

Abstract: Objective To explore the application value and feasibility of veno-venous extracorporeal membrane oxygenation (VV-ECMO) in the treatment of patients infected with H10N3 avian influenza complicated with severe acute respiratory distress syndrome (ARDS). Method A retrospective analysis was performed on the process and effect of VV-ECMO adjuvant treatment in the first case of human infection with H10N3 avian influenza complicated with ARDS in Guangxi. Result The main clinical manifestations of the patient were fever, cough and shortness of breath. The patient was confirmed to be infected with H10N3 avian influenza by the Chinese Center for Disease Control and Prevention (China CDC) through deep sequencing of influenza virus in respiratory samples. After receiving VV-ECMO supportive treatment, the pulmonary lesions were absorbed, and the patient ultimately recovered. Conclusion The application of VV-ECMO in patients infection with H10N3 avian influenza complicated with ARDS has shown remarkable therapeutic effects. It can efficiently provide oxygenation and remove carbon dioxide, winning precious time for disease control and pulmonary function recovery, and significantly improving patient survival rates.

Key words: Human infection with H10N3 avian influenza, Acute respiratory distress syndrome, Veno-venous extracorporeal membrane oxygenation

CLC Number:

R511.7

Tan Shiji, Wei Jing, Liu Sheng, Lu Ning, Lu Yuming, Li Youling, Li Mei, Chen Yuehua, Cen Ping, Xie Zhouhua. Analysis of veno-venous extracorporeal membrane oxygenation treatment strategies and literature review for the first case of human infection with H10N3 avian influenza complicated by severe acute respiratory distress syndrome in Guangxi[J]. Electronic Journal of Emerging Infectious Diseases, 2025, 10(2): 1-6.

References

[1] JING J, WANG L, WANG G, et al.A human infection case with avian-origin H10N3 influenza virus[J]. Quant Imaging Med Surg, 2021, 11(10):4508-4510.
[2] ZHAO Z, LUO S, GAO Y,et al.A case report of human infection with avian influenza H10N3 with a complex respiratory disease history[J]. BMC Infect Dis, 2024, 24(1):918.
[3] LIU K, QI X, BAO C, et al.Novel H10N3 avian influenza viruses: a potential threat to public health[J]. Lancet Microbe, 2024, 5(5):e417.
[4] ZHANG Y, SHI J, CUI P, et al.Genetic analysis and biological characterization of H10N3 influenza A viruses isolated in China from 2014 to 2021[J]. J Med Virol, 2023, 95(2):e28476.
[5] ZHU W, YANG L, HAN X, et al.Origin, pathogenicity, and transmissibility of a human isolated influenza A(H10N3) virus from China[J]. Emerg Microbes Infect, 2025, 14(1):2432364.
[6] 韩冰,蒋荣猛.《人感染禽流感诊疗方案(2024年版)》解读[J/CD].新发传染病电子杂志,2024, 9(5):94-97.
[7] GAO HN, LU HZ, CAO B, et al.Clinical findings in 111 cases of influenza A (H7N9) virus infection[J]. N Engl J Med, 2013, 368(24):2277-2285.
[8] LAMPEJO TI.Is combination antiviral therapy for influenza the optimal approach?[J]. Lancet Infect Dis, 2022, 22(5):587-588.
[9] HIGUERA IGLESIAS AL, KUDO K, MANABE T, et al.Reducing occurrence and severity of pneumonia due to pandemic H1N1 2009 by early oseltamivir administration: a retrospective study in Mexico[J]. PLoS One, 2011, 6(7):e21838.
[10] DENG LS, YUAN J, DING L, et al.Comparison of patients hospitalized with COVID-19, H7N9 and H1N1[J]. Infect Dis Poverty, 2020, 9(1):163.
[11] VAN DEN BRAND JM, HAAGMANS BL, VAN RIEL D, et al. The pathology and pathogenesis of experimental severe acute respiratory syndrome and influenza in animal models[J]. J Comp Pathol, 2014, 151(1):83-112.
[12] LIU Q, DU J, YU X, et al.miRNA-200c-3p is crucial in acute respiratory distress syndrome[J]. Cell Discov. 2017, 3:17021.
[13] HEROLD S, BECKER C, RIDGE KM,et al.Influenza virus-induced lung injury: pathogenesis and implications for treatment[J]. Eur Respir J, 2015, 45(5):1463-1478.
[14] MEYBOUDI SM, RABORI VS, SALKHORDE D, et al.Dexamethasone in COVID-19 treatment: Analyzing monotherapy and combination therapy approaches[J]. Cytokine, 2024, 184:156794.
[15] MORENO G, RODRÍGUEZ A, REYES LF,et al. Corticosteroid treatment in critically ill patients with severe influenza pneumonia: a propensity score matching study[J]. Intensive Care Med, 2018, 44(9):1470-1482.
[16] ISHIKAWA N, HATTORI N, YOKOYAMA A,et al.Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases[J]. Respir Investig, 2012, 50(1):3-13.
[17] BLUM JM, LYNCH WR, COOPERSMITH CM.Clinical and billing review of extracorporeal membrane oxygenation[J]. Chest, 2015, 147(6):1697-1703.
[18] BULL T, CORLEY A, SMYTH DJ, et al.Extracorporeal membrane oxygenation line-associated complications: in vitro testing of cyanoacrylate tissue adhesive and securement devices to prevent infection and dislodgement[J]. Intensive Care Med Exp, 2018, 6(1):6.
[19] JAVIDFAR J, ZAAQOQ AM, YAMASHITA MH, et al.Venovenous extracorporeal membrane oxygenation in obese patients[J]. JTCVS Tech, 2021, 10:335-348.
[20] MARCHENKO VA, ZHILINSKAYA IN.Endothelial activation and dysfunction caused by influenza A virus (Alphainfluenzavirus influenzae)[J]. Vopr Virusol, 2024, 69(6):465-478.
[21] SCHMIDT M, PHAM T, ARCADIPANE A, et al.Mechanical Ventilation Management during Extracorporeal Membrane Oxygenation for Acute Respiratory Distress Syndrome. An International Multicenter Prospective Cohort[J]. Am J Respir Crit Care Med, 2019, 200(8):1002-1012.
[22] CHARRON C, BOUFERRACHE K, CAILLE V, et al.Routine prone positioning in patients with severe ARDS: feasibility and impact on prognosis[J]. Intensive Care Med, 2011, 37(5):785-790.
[23] VIGNON P, EVRARD B, ASFAR P, et al.Fluid administration and monitoring in ARDS: which management?[J]. Intensive Care Med, 2020, 46(12):2252-2264.
[25] TONNA JE, ABRAMS D, BRODIE D, et al.Management of Adult Patients Supported with Venovenous Extracorporeal Membrane Oxygenation (VV-ECMO): Guideline from the Extracorporeal Life Support Organization (ELSO)[J]. ASAIO J, 2021, 67(6):601-610.
[26] 国家卫生健康委办公厅.成人体外膜肺氧合技术操作规范(2024 年版)[EB/OL].[2025-03-07]. http://www.nhc.gov.cn/yzygj/s3585/202411/fc18e0056d8b4a4f8710f90e7db902d3.shtml.
[27] AIT HSSAIN A, VAHEDIAN-AZIMI A, IBRAHIM AS, et al.A systematic review and meta-analysis on the incidence, risk factors, and outcomes of nosocomial infections in adult patients supported by extracorporeal membrane oxygenation (ECMO)[J]. Crit Care, 2024, 28(1):158.
[28] HONG TH, KUO SW, HU FC, et al.Do interleukin-10 and superoxide ions predict outcomes of cardiac extracorporeal membrane oxygenation patients?[J]. Antioxid Redox Signal, 2014, 20(1):60-80.
[29] MCILWAIN RB, TIMPA JG, KURUNDKAR AR,et al.Plasma concentrations of inflammatory cytokines rise rapidly during ECMO-related SIRS due to the release of preformed stores in the intestine[J]. Lab Invest, 2010, 90(1):128-139.